We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+12.57%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$750M
AUM Growth
+$262M
Cap. Flow
+$205M
Cap. Flow %
27.3%
Top 10 Hldgs %
28.71%
Holding
137
New
15
Increased
36
Reduced
40
Closed
5

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$14.3M
2
ALGN icon
Align Technology
ALGN
+$13.8M
3
WBA
Walgreens Boots Alliance
WBA
+$13.5M
4
AMGN icon
Amgen
AMGN
+$12M
5
CNC icon
Centene
CNC
+$9.49M

Top Sells

Rank Stock Value
1
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$4.67M
2
SYK icon
Stryker
SYK
+$4.15M
3
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$1.91M
4
BDX icon
Becton Dickinson
BDX
+$1.79M
5
ZBH icon
Zimmer Biomet
ZBH
+$1.75M

Sector Composition

Rank Sector Weight
1 Healthcare 92.09%
2 Financials 0.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTA icon
76
Prothena Corp
PRTA
$453M
$2.29M 0.3%
41,000
– –
MASI
77
DELISTED
Masimo
MASI
$2.15M 0.29%
23,000
-7,000
-23% -$576K
TMO icon
78
Thermo Fisher Scientific
TMO
$198B
$2M 0.27%
13,000
-3,000
-19% -$459K
CYTO
79
DELISTED
Altamira Therapeutics Ltd
CYTO
$2M 0.27%
27
– –
HCA icon
80
HCA Healthcare
HCA
$82.3B
$1.9M 0.25%
21,300
-2,500
-11% -$208K
LH icon
81
Labcorp
LH
$23.2B
$1.86M 0.25%
15,132
+5,820
+63% +$689K
ANGO icon
82
AngioDynamics
ANGO
$558M
$1.76M 0.24%
101,700
– –
MRK icon
83
Merck
MRK
$315B
$1.75M 0.23%
28,820
– –
XENT
84
DELISTED
Intersect ENT, Inc
XENT
$1.72M 0.23%
100,000
-30,000
-23% -$420K
PFE icon
85
Pfizer
PFE
$143B
$1.71M 0.23%
52,700
– –
CAH icon
86
Cardinal Health
CAH
$53.5B
$1.63M 0.22%
20,000
– –
ACAD icon
87
Acadia Pharmaceuticals
ACAD
$4.38B
$1.55M 0.21%
45,000
– –
RDUS
88
DELISTED
Radius Health, Inc.
RDUS
$1.41M 0.19%
36,500
-3,500
-9% -$147K
PTLA
89
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$1.41M 0.19%
36,000
– –
ENDP
90
DELISTED
Endo International plc
ENDP
$1.28M 0.17%
115,000
-9,000
-7% -$112K
TFX icon
91
Teleflex
TFX
$5.96B
$1.26M 0.17%
6,500
– –
BMY icon
92
Bristol-Myers Squibb
BMY
$124B
$1.25M 0.17%
23,000
– –
BIVV
93
DELISTED
Bioverativ Inc. Common Stock
BIVV
$1.24M 0.17%
+22,750
New +$1.12M
ZLTQ
94
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$1.22M 0.16%
22,000
-38,000
-63% -$1.91M
GMED icon
95
Globus Medical
GMED
$10.5B
$1.19M 0.16%
40,000
-47,700
-54% -$1.3M
CLVS
96
DELISTED
Clovis Oncology, Inc.
CLVS
$1.18M 0.16%
18,500
-1,500
-8% -$91.2K
NVDQ
97
DELISTED
Novadaq Technologies Inc.
NVDQ
$1.17M 0.16%
150,000
-80,000
-35% -$567K
ESPR
98
DELISTED
Esperion Therapeutics
ESPR
$1.13M 0.15%
32,000
-8,000
-20% -$183K
EXEL icon
99
Exelixis
EXEL
$14.1B
$1.13M 0.15%
52,000
-8,000
-13% -$163K
KITE
100
DELISTED
Kite Pharma, Inc.
KITE
$1.1M 0.15%
14,000
– –
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2017 Portfolio in Review

As of Q1 2017, Bellevue Group held 137 positions worth $750M, up 54% from $488M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Bellevue Group deployed $205M of net new capital in Q1 2017, opening 15 new positions and adding to 36 existing holdings. Its largest new stake was Align Technology: 136,200 shares worth $15.6M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 92% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Stryker, an estimated $4.15M trimmed.

  • Bellevue Group's largest Q1 2017 buy was Align Technology: 136,200 shares worth $15.6M.
  • Bellevue Group added most to Elevance Health in Q1 2017, an estimated $14.3M increase.
  • Bellevue Group's biggest Q1 2017 reduction was Stryker, cutting an estimated $4.15M.
  • Bellevue Group fully exited Ariad Pharmaceuticals Inc in Q1 2017, selling an estimated $4.67M.
  • Bellevue Group's ten largest holdings make up 29% of its $750M portfolio in Q1 2017.
  • Bellevue Group opened 15 new positions and closed 5 in Q1 2017.
  • Bellevue Group's portfolio value rose 54% quarter-over-quarter to $750M.

Based on Bellevue Group's 13F filing for Q1 2017, filed 11 May 2017.